Background & Aims
Prevalence of serum autoantibodies in chronic hepatitis C (HCV) patients is higher than that in the general population. Interferon may induce autoimmune manifestations in patients treated with peg-interferon and ribavirin. Effect of autoantibody seropositivity and treatment response are limited and controversial.
To detect the prevalence of serum autoantibodies in patients with chronic HCV and impact on histopathology and treatment response.